Phenotype of Cells Generated by Human CD34+ or CD34+CD38low Cells Sorted From the Marrow of SCID or NOD-SCID Mice Transplanted With Human CB-MNC or CD34+ Cells and Cultured With MS-5 Stromal Cells
Experiment No. . | Cells Injected . | Mice . | Time (wk) . | Sorted Cells . | Time in Culture (wk) . | 24 Wells4-150 . | Cultures at Limiting Dilutions . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | CD11b+ or CD15+ . | CD19+ . | Cells/Well . | No. of Wells . | Positive/Total Wells Analyzed4-151 . | . | . | ||
. | . | . | . | . | . | . | . | . | . | CD19+ . | CD19+ CD15− . | CD19− CD15+ . | . | . |
. | . | . | . | . | . | . | . | . | . | CD15+/CD11b+ . | . | . | . | . |
1 | MNC | SCID | 4 | 34+38low | 4 | 59% | 5% | 1 | 180 | 5/80 | 4/80 | 10/80 | ||
2 | MNC | SCID | 7 | 34+38low | 7 | 25% | 10% | ND | ND | ND | ND | ND | ||
3 | MNC | NOD-SCID | 4 | 34+38low | 4 | ND | ND | 1 | 240 | 3/13 | 2/13 | 8/13 | ||
10 | 60 | 8/18 | 4/18 | 5/18 | ||||||||||
4 | CD34+ | NOD-SCID | 7 | 34+38low | 4 | 39% | 5% | 1 | 60 | 0/12 | 9/12 | 3/12 | ||
10 | 60 | 13/18 | 3/18 | 2/18 | ||||||||||
50 | 60 | 10/10 | 0/10 | 0/10 | ||||||||||
5 | CD34+ | NOD-SCID | 5 | 34+ | 7 | 25% | 8% | ND | ND | ND | ND | ND |
Experiment No. . | Cells Injected . | Mice . | Time (wk) . | Sorted Cells . | Time in Culture (wk) . | 24 Wells4-150 . | Cultures at Limiting Dilutions . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | CD11b+ or CD15+ . | CD19+ . | Cells/Well . | No. of Wells . | Positive/Total Wells Analyzed4-151 . | . | . | ||
. | . | . | . | . | . | . | . | . | . | CD19+ . | CD19+ CD15− . | CD19− CD15+ . | . | . |
. | . | . | . | . | . | . | . | . | . | CD15+/CD11b+ . | . | . | . | . |
1 | MNC | SCID | 4 | 34+38low | 4 | 59% | 5% | 1 | 180 | 5/80 | 4/80 | 10/80 | ||
2 | MNC | SCID | 7 | 34+38low | 7 | 25% | 10% | ND | ND | ND | ND | ND | ||
3 | MNC | NOD-SCID | 4 | 34+38low | 4 | ND | ND | 1 | 240 | 3/13 | 2/13 | 8/13 | ||
10 | 60 | 8/18 | 4/18 | 5/18 | ||||||||||
4 | CD34+ | NOD-SCID | 7 | 34+38low | 4 | 39% | 5% | 1 | 60 | 0/12 | 9/12 | 3/12 | ||
10 | 60 | 13/18 | 3/18 | 2/18 | ||||||||||
50 | 60 | 10/10 | 0/10 | 0/10 | ||||||||||
5 | CD34+ | NOD-SCID | 5 | 34+ | 7 | 25% | 8% | ND | ND | ND | ND | ND |
Cord blood cells (20 × 106 MNC or 25 to 50 × 104 CD34+ cells) were injected intravenously to either SCID (experiments no. 1 and 2) or NOD-SCID (experiments 3 through 5) mice. After 4 to 7 weeks, mice were killed and marrow cells were analyzed for the presence of human cells (see Table 3). Human CD34+CD38low cells were sorted by FACS and used to initiate long-term cocultures on MS-5 cells as described in the Materials and Methods. Cells were incubated either in 24 wells (2,500 to 5,000 CD34+CD38low cells/well) or at limiting dilutions in 96-well plates. After 5 to 7 weeks in culture, the phenotype of cultured cells was analyzed by labeling with antibodies directed against human CD19 and CD15 (or CD11b).
Abbreviation: ND, not done.
Percentages represent the proportion of nucleated cells of the indicated phenotype.
Total wells analyzed represent the number of wells in which enough cells were detectable to allow reliable phenotypic analysis. Positive wells represent the number of these analyzed wells that contain cells of the indicated phenotype.